| HOME >> MEDICINE >> TECHNOLOGY |
GENEVA, Oct. 26, 2011 /PRNewswire-USNewswire/ -- The World Intellectual Property Organization (WIPO), in an unprecedented collaboration with leading pharmaceutical companies and BIO Ventures for Global Health (BVGH), launched today WIPO Re:Search, a new consortium where public and private sector organizations share valuable intellectual property (IP) and expertise with the global health research community to promote development of new drugs, vaccines, and diagnostics to treat neglected tropical diseases, malaria, and tuberculosis.
In WIPO Re:Search, Alnylam Pharmaceuticals, AstraZeneca, Eisai, GlaxoSmithKline, MSD(1), Novartis, Pfizer, and Sanofi are collaborating with WIPO, BVGH, the U.S. National Institutes of Health (NIH), and multiple non-profit research organizations. These include the California Institute of Technology, the Center for World Health & Medicine, the Drugs for Neglected Diseases initiative, Fundacao Oswaldo Cruz (Fiocruz), Massachusetts Institute of Technology, Medicines for Malaria Venture, PATH, the South African Medical Research Council, the Swiss Tropical and Public Health Institute, the University of California, Berkeley, and the University of Dundee (UK).
"WIPO Re:Search is a ground breaking example of how a multi-stakeholder coalition can put IP to work for social benefit," said WIPO Director General Francis Gurry. "By joining WIPO Re:Search, companies and researchers commit to making selected intellectual property assets available under royalty-free licenses to qualified researchers anywhere in the world for research and development on neglected tropical diseases, malaria, and tuberculosis. This commitment should accelerate the development of medicines, vaccines, and diagnostics for these diseases."
According to the World Health Organization (WHO), neglected tropical diseases today impair the lives of an estimated 1 billion people. The WHO provides t
'/>"/>
| SOURCE BIO Ventures for Global Health Copyright©2010 PR Newswire. All rights reserved |